Optimizing -lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

被引:84
作者
Delattre, Isabelle K. [1 ,2 ]
Taccone, Fabio S. [3 ]
Jacobs, Frederique [4 ]
Hites, Maya [4 ]
Dugernier, Thierry [5 ]
Spapen, Herbert [6 ]
Laterre, Pierre-Francois [7 ]
Wallemacq, Pierre E. [2 ]
Van Bambeke, Francoise [1 ]
Tulkens, Paul M. [1 ]
机构
[1] Catholic Univ Louvain, Louvain Drug Res Inst, Brussels, Belgium
[2] Clin Univ St Luc, Dept Clin Chem, Brussels, Belgium
[3] Hop Erasme, Dept Intens Care, Brussels, Belgium
[4] Hop Erasme, Dept Infect Dis, Brussels, Belgium
[5] Clin St Pierre, Dept Intens Care, Ottignies, Belgium
[6] Univ Ziekenhuis Brussel, Dept Intens Care, Brussels, Belgium
[7] Clin Univ St Luc, Dept Intens Care, Brussels, Belgium
关键词
B-lactams; critically-ill patients; PK; PD targets; first dose; maximal efficacy; CARE-UNIT PATIENTS; MINIMUM INHIBITORY CONCENTRATION; FEBRILE NEUTROPENIC PATIENTS; RENAL REPLACEMENT THERAPY; CONTINUOUS VENOVENOUS HEMODIAFILTRATION; STEADY-STATE PHARMACOKINETICS; DEFINING ANTIBIOTIC LEVELS; MORBIDLY OBESE-PATIENTS; LOWER RESPIRATORY-TRACT; POPULATION PHARMACOKINETICS;
D O I
10.1080/14787210.2017.1338139
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: The pharmacokinetic/pharmacodynamic index determining -lactam activity is the percentage of the dosing interval (%T) during which their free serum concentration remains above a critical threshold over the minimum inhibitory concentration (MIC). Regrettably, neither the value of %T nor that of the threshold are clearly defined for critically-ill patients.Areas covered: We review and assess the targets proposed for -lactams in critical illness by screening the literature since 1997. Depending on the study intention (clinical cure vs. suppression of resistance), targets proposed range from 20%T>1xMIC to 100%T>5xMIC. Assessment and comparative analysis of their respective clinical efficacy suggest that a value of 100%T>4xMIC may be needed. Simulation studies, however, show that this target will not be reached at first dose for the majority of critically-ill patients if using the most commonly recommended doses.Expert commentary: Considering that critically-ill patients are highly vulnerable and likely to experience antibiotic underexposure, and because effective initial treatment is a key determinant of clinical outcome, we support the use of a target of 100%T>4xMIC, which could not only maximize efficacy but also minimize emergence of resistance. Clinical and microbiological studies are needed to test for the feasibility and effectiveness of reaching such a demanding target.
引用
收藏
页码:677 / 688
页数:12
相关论文
共 104 条
  • [1] Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort
    Abdul-Aziz, Mohd H.
    Lipman, Jeffrey
    Akova, Murat
    Bassetti, Matteo
    De Waele, Jan J.
    Dimopoulos, George
    Dulhunty, Joel
    Kaukonen, Kirsi-Maija
    Koulenti, Despoina
    Martin, Claude
    Montravers, Philippe
    Rello, Jordi
    Rhodes, Andrew
    Starr, Therese
    Wallis, Steven C.
    Roberts, Jason A.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (01) : 196 - 207
  • [2] Abdul-Aziz MH, 2012, MINERVA ANESTESIOL, V78, P94
  • [3] Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia
    Aitken, Samuel L.
    Altshuler, Jerry
    Guervil, David J.
    Hirsch, Elizabeth B.
    Ostrosky-Zeichner, Luis L.
    Ericsson, Charles D.
    Tam, Vincent H.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 (05) : 541 - 544
  • [4] Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients
    Akers, Kevin S.
    Niece, Krista L.
    Chung, Kevin K.
    Cannon, Jeremy W.
    Cota, Jason M.
    Murray, Clinton K.
    [J]. JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2014, 77 : S163 - S170
  • [5] Animal model pharmacokinetics and pharmacodynamics: a critical review
    Andes, D
    Craig, WA
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) : 261 - 268
  • [6] Angus B. J., 2000, British Journal of Clinical Pharmacology, V50, P184
  • [7] Pharmacokinetics and pharmacodynamics of meropenern in febrile neutropenic patients with bacteremia
    Ariano, RE
    Nyhlén, A
    Donnelly, JP
    Sitar, DS
    Harding, GKM
    Zelenitsky, SA
    [J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (01) : 32 - 38
  • [8] Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis
    Asin-Prieto, Eduardo
    Rodriguez-Gascon, Alicia
    Troconiz, Inaki F.
    Soraluce, Amaia
    Maynar, Javier
    Angel Sanchez-Izquierdo, Jose
    Isla, Arantxazu
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (01) : 180 - 189
  • [9] Pharmacokinetics of an Extended 4-hour Infusion of Piperacillin-Tazobactam in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
    Awissi, Don-Kelena
    Beauchamp, Annie
    Hebert, Elisabeth
    Lavigne, Viviane
    Munoz, Danya Lucia
    Lebrun, Genevieve
    Savoie, Michel
    Fagnan, Mylene
    Amyot, Julie
    Tetreault, Nicolas
    Robitaille, Robert
    Varin, France
    Lavallee, Christian
    Pichette, Vincent
    Leblanc, Martine
    [J]. PHARMACOTHERAPY, 2015, 35 (06): : 600 - 607
  • [10] Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?
    Bassetti, Matteo
    Welte, Tobias
    Wunderink, Richard G.
    [J]. CRITICAL CARE, 2016, 20